Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Dranitsaris

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
International Journal of Technology Assessment in Health Care|July 17, 1999
Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth?G Dranitsaris
Pharmacoeconomics|January 6, 2000
Clinical and economic considerations of empirical antibacterial therapy of febrile neutropenia in cancerG Dranitsaris
Anti-Cancer Drugs|January 16, 1999
Treatment of non-Hodgkin's lymphomaG Dranitsaris
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 24, 1997
A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: an assessment of amifostine cytoprotectionG Dranitsaris
Pharmacoeconomics|April 7, 1996
Using filgrastim efficientlyG Dranitsaris
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 28, 1999
Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancerG Dranitsaris, T Hsu
Leukemia & Lymphoma|March 1, 1995
Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphomaG Dranitsaris, S B Sutcliffe
European Journal of Cancer (Oxford, England : 1990)|December 1, 1995
Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapyG Dranitsaris, T M Tran
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 5, 2002
Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention studyG Dranitsaris, P Leung, D Warr
Pharmacoeconomics|May 7, 1997
Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphomaG Dranitsaris, C Altmayer, I Quirt
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
International Journal of Technology Assessment in Health Care|July 17, 1999
Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth?G Dranitsaris
Pharmacoeconomics|January 6, 2000
Clinical and economic considerations of empirical antibacterial therapy of febrile neutropenia in cancerG Dranitsaris
Anti-Cancer Drugs|January 16, 1999
Treatment of non-Hodgkin's lymphomaG Dranitsaris
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 24, 1997
A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: an assessment of amifostine cytoprotectionG Dranitsaris
Pharmacoeconomics|April 7, 1996
Using filgrastim efficientlyG Dranitsaris
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 28, 1999
Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancerG Dranitsaris, T Hsu
Leukemia & Lymphoma|March 1, 1995
Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphomaG Dranitsaris, S B Sutcliffe
European Journal of Cancer (Oxford, England : 1990)|December 1, 1995
Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapyG Dranitsaris, T M Tran
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 5, 2002
Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention studyG Dranitsaris, P Leung, D Warr
Pharmacoeconomics|May 7, 1997
Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphomaG Dranitsaris, C Altmayer, I Quirt
Pageof 5